Blog
RSS FeedPosted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Apr 2022
Life Saving Drugs Program – medicines reviews recommendations
7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...
Posted by Michael Wonder on 01 Apr 2022
Public Summary Documents – December 2021 PBAC meeting
1 April 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the December 2021 PBAC ...
Posted by Michael Wonder on 01 Apr 2022
ACE releases latest trance of drug guidances (April 2022)
1 April 2022 - The Agency for Clinical Effectiveness has released another batch of drug guidances. ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...
Posted by Michael Wonder on 18 Mar 2022
Public summary documents – November 2021 PBAC meeting (first time rejections and deferrals)
18 March 2022 - The Public Summary Documents (first time rejections and deferrals) from the November 2021 PBAC meeting are now ...
Posted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
Posted by Michael Wonder on 17 Mar 2022
COVID-19 vaccine weekly safety report (17 March 2022)
17 March 2022 - To 13 March 2022, the TGA has received 457 reports which have been assessed as likely to ...
Posted by Michael Wonder on 04 Mar 2022
Public summary documents – November 2021 PBAC meeting
4 March 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2021 PBAC ...
Posted by Michael Wonder on 15 Feb 2022
Office of Generic Drugs 2021 Annual Report
14 February 2022 - Ensuring high quality, affordable generic drugs are available to the American public. ...
Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 25 Jan 2022
ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
Posted by Michael Wonder on 14 Jan 2022
Advancing health through innovation: new drug therapy approvals 2021
13 January 2022 - The FDA’s Center for Drug Evaluation and Research has issued its report, Advancing Health Through Innovation: New ...